The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
about
Targeting of erbB3 receptor to overcome resistance in cancer treatmentERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaInfluence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cellsHigh-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation.The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cellsADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer.Therapeutic targets and new directions for antibodies developed for ovarian cancer.MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseAntibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.HER3/ErbB3, an emerging cancer therapeutic target.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.HER3 expression is correlated to distally located and low-grade colon cancer.A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.Targeting protein quality control pathways in breast cancer.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells.Activation of TNF-α/NF-κB axis enhances CRL4BDCAF11 E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver.MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
P2860
Q26864668-C3670BC5-C12D-4997-AFB4-A69F5EB65C84Q33772914-DAF76AAF-6CCD-4CCD-9E73-84C0E6B13E59Q33875560-033FDD88-B60E-4194-A771-9B1B6B2B6723Q35914683-C28E1F11-62B8-43CC-81CC-F2449EC45FC2Q35918911-30603586-7DF6-4DB1-ADE2-86B107B5D5A7Q36354166-2F16A5BB-9B3B-4D9C-880C-C61A9DE9A528Q36771985-2701A1BD-4BEF-429A-8CBB-E660E54E108EQ36962935-32A985DD-1A02-4F83-AF59-243F7AD01391Q37151282-C64B9A1F-E65B-435F-8DA6-209593B09A7DQ37397674-662F6B34-B12B-4912-BA79-71A176E5388BQ37437269-E7D1C273-20C6-454F-B2D1-F8A8096AF893Q37722926-2CB85181-08C1-4CC6-AE18-D34B4D2DFE73Q38214511-5B6A6159-EAE8-4E4C-BB11-288EB5EE04D9Q38615197-F84DC695-86CD-414E-B26F-4075E16A49A2Q38623361-A78FBB20-7EE6-4882-9F07-53F118E56B4BQ38729111-BF7CA057-17C5-4E99-8DD0-F3C9C49024A1Q38760738-AB4D1177-A260-498E-AC8F-2AABE49E4923Q38867798-ED414FE8-44A6-46FF-8FA0-A82E5EA80D67Q40918277-42C3A158-0B5F-4E99-A7E0-FE1F1ED30A2DQ45959066-4B87AFDA-3D2C-4A60-8D17-B415C484BA8CQ46087491-5B70F5FA-B159-4EF9-AD99-6DED21C3696AQ47158524-D212266A-038A-4E37-88B0-F6DD8F8156BFQ47350657-2594E388-02DE-40AD-8CC1-EA349290105EQ49607728-70275B31-7AF7-43AD-B1B4-DB2CCA26EE82Q53640616-51727776-A679-458E-A347-98C523D2A2E7Q55374436-3D8E0249-E409-4449-BF7B-3C46DE1CD4A5Q55710176-CDAADFFE-81DC-4072-8333-F4377DC65DC6Q58796351-94B4D940-720A-4860-B2EE-D01B638C3DC2
P2860
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The anti-erbB3 antibody MM-121 ...... resistant breast cancer cells.
@en
The anti-erbB3 antibody MM-121 ...... resistant breast cancer cells.
@nl
type
label
The anti-erbB3 antibody MM-121 ...... resistant breast cancer cells.
@en
The anti-erbB3 antibody MM-121 ...... resistant breast cancer cells.
@nl
prefLabel
The anti-erbB3 antibody MM-121 ...... resistant breast cancer cells.
@en
The anti-erbB3 antibody MM-121 ...... resistant breast cancer cells.
@nl
P2093
P2860
P356
P1433
P1476
The anti-erbB3 antibody MM-121 ...... resistant breast cancer cells.
@en
P2093
Jianxiang Wang
Jingcao Huang
Shuiliang Wang
XiaoHe Yang
P2860
P2888
P356
10.1186/1476-4598-12-134
P50
P577
2013-11-11T00:00:00Z
P5875
P6179
1044606689